Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$456.95 USD
+6.15 (1.36%)
Updated May 24, 2024 04:00 PM ET
After-Market: $457.02 +0.07 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Vertex Pharmaceuticals Incorporated [VRTX]
Reports for Purchase
Showing records 301 - 320 ( 326 total )
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Initiating Coverage with a Buy Rating and Price Target of $45
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
2010 AASLD Abstract Titles Review - Second Wave Including Late-Breakers
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Boceprevir Topline May Be a Temporary Relief to Vertex
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Biotechnology / Biopharmaceuticals -2010 AASLD Abstract Titles Review - First Wave Without Late Breakers
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Lowering PT to $40 on Anticipated Stronger Competition
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Interim TMC435 Data Impressive; Remains a Strong Competitor to Telaprevir Although >2 Years Behind
Provider: WEDBUSH SECURITIES INC.
Analyst: XU Y
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
ADVANCE Is As Good As It Can Get - Upgrade to Relative -NEUTRAL on Minimized Downside Risk.
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Bulls and Bears Balancing Out at EASL - What to Expect Next?
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
Q1:10 Earnings Non-Event; Phase III Data Next
Provider: WEDBUSH SECURITIES INC.
Company: Vertex Pharmaceuticals Incorporated
Industry: Medical - Biomedical and Genetics
EASL 2010 Preview Part I.Summary of Oral Presentations.
Provider: WEDBUSH SECURITIES INC.
Analyst: XU K